Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038048 · ClinicalTrials.gov registry record · NA
30g vs 33g Needle for Intravitreal Injections
A NA study of Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03038048 is a NA study of Age-related Macular Degeneration and Diabetic Macular Edema that has completed, run by Wills Eye. The registered enrollment target is 50 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03038048, a NA study of Age-related Macular Degeneration and Diabetic Macular Edema, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
We are comparing the patient experience between the standard 30 g needle to the smaller 33 g needle for intravitreal injections of ranabizumab or aflibercept for age related macular degeneration, diabetic macular edema, or retina vein occlusions.
Conditions Studied
Interventions
- PROCEDURE Varying needle size with intravitreal ranibizumab or aflibercept
Study Locations (1)
Pennsylvania
- Mid Atlantic Retina- Wills Eye Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2017-04-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038048
The ClinicalTrials.gov registry entry for NCT03038048 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Varying needle size with intravitreal ranibizumab or aflibercept is the first listed.
NCT03038048 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03038048 about?
NCT03038048 is a clinical study titled "30g vs 33g Needle for Intravitreal Injections". We are comparing the patient experience between the standard 30 g needle to the smaller 33 g needle for intravitreal injections of ranabizumab or aflibercept for age related macular degeneration, diabetic macular edema, or retina vein occlusions.
What is the current status of trial NCT03038048?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2017-01-27. Estimated completion is 2017-04-27.
What conditions does trial NCT03038048 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion.
What interventions are being tested in trial NCT03038048?
The interventions under investigation include: Varying needle size with intravitreal ranibizumab or aflibercept (PROCEDURE).
Who is sponsoring clinical trial NCT03038048?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03038048 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
Explore more on PlainTrial
Age-related Macular Degeneration
All registered trials for this condition
Diabetic Macular Edema
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.